A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.

Michael Friedlander; Tarek Meniawy; Ben Markman; Linda R. Mileshkin; Paul Harnett; Michael Millward; J. Lundy; A. E. Freimund; C. Norris; S Mu; V Paton; L Wang; Bo Gao

doi:10.1200/JCO.2018.36.5_suppl.48

A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.

Michael Friedlander, Tarek Meniawy, Ben Markman, Linda R. Mileshkin, Paul Harnett, Michael Millward, J. Lundy, A. E. Freimund, C. Norris, S Mu, V Paton, L Wang, Bo Gao

UWA Medical School

Research output: Contribution to journal › Abstract/Meeting Abstract

Original language	English
Number of pages	2
Journal	Journal of Clinical Oncology
Volume	36
Issue number	5
DOIs	https://doi.org/10.1200/JCO.2018.36.5_suppl.48
Publication status	Published - 10 Feb 2018
Event	ASCO-SITC Clinical Immuno-Oncology Symposium - San Francisco, Canada Duration: 25 Jan 2018 → 27 Jan 2018

Access to Document

10.1200/JCO.2018.36.5_suppl.48

Cite this

Friedlander, M., Meniawy, T., Markman, B., Mileshkin, L. R., Harnett, P., Millward, M., Lundy, J., Freimund, A. E., Norris, C., Mu, S., Paton, V., Wang, L., & Gao, B. (2018). A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors. Journal of Clinical Oncology, 36(5). https://doi.org/10.1200/JCO.2018.36.5_suppl.48

Friedlander, Michael ; Meniawy, Tarek ; Markman, Ben ; Mileshkin, Linda R. ; Harnett, Paul ; Millward, Michael ; Lundy, J. ; Freimund, A. E. ; Norris, C. ; Mu, S ; Paton, V ; Wang, L ; Gao, Bo. / A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors. In: Journal of Clinical Oncology. 2018 ; Vol. 36, No. 5.

@article{42f3f566249449e0ab21a3f09c717ad3,

title = "A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.",

author = "Michael Friedlander and Tarek Meniawy and Ben Markman and Mileshkin, {Linda R.} and Paul Harnett and Michael Millward and J. Lundy and Freimund, {A. E.} and C. Norris and S Mu and V Paton and L Wang and Bo Gao",

year = "2018",

month = feb,

day = "10",

doi = "10.1200/JCO.2018.36.5_suppl.48",

language = "English",

volume = "36",

journal = "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "5",

note = "ASCO-SITC Clinical Immuno-Oncology Symposium ; Conference date: 25-01-2018 Through 27-01-2018",

}

Friedlander, M, Meniawy, T, Markman, B, Mileshkin, LR, Harnett, P, Millward, M, Lundy, J, Freimund, AE, Norris, C, Mu, S, Paton, V, Wang, L & Gao, B 2018, 'A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.', Journal of Clinical Oncology, vol. 36, no. 5. https://doi.org/10.1200/JCO.2018.36.5_suppl.48

A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors. / Friedlander, Michael; Meniawy, Tarek; Markman, Ben; Mileshkin, Linda R.; Harnett, Paul; Millward, Michael; Lundy, J.; Freimund, A. E.; Norris, C.; Mu, S; Paton, V; Wang, L; Gao, Bo.

In: Journal of Clinical Oncology, Vol. 36, No. 5, 10.02.2018.

Research output: Contribution to journal › Abstract/Meeting Abstract

TY - JOUR

T1 - A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.

AU - Friedlander, Michael

AU - Meniawy, Tarek

AU - Markman, Ben

AU - Mileshkin, Linda R.

AU - Harnett, Paul

AU - Millward, Michael

AU - Lundy, J.

AU - Freimund, A. E.

AU - Norris, C.

AU - Mu, S

AU - Paton, V

AU - Wang, L

AU - Gao, Bo

PY - 2018/2/10

Y1 - 2018/2/10

U2 - 10.1200/JCO.2018.36.5_suppl.48

DO - 10.1200/JCO.2018.36.5_suppl.48

M3 - Abstract/Meeting Abstract

VL - 36

JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

SN - 0732-183X

IS - 5

T2 - ASCO-SITC Clinical Immuno-Oncology Symposium

Y2 - 25 January 2018 through 27 January 2018

ER -